A Further Stride in the IMMray PanCan-d Verification Study
Immunovia announces positive results from the verification study, the last stride towards the launch of IMMray PanCan-d.
FREMONT, CA: Immunovia, a diagnostic company that provides highly accurate blood tests for the early identification of cancer and autoimmune diseases, announces positive results from the verification study and will now commence the validation study, the last stride towards the release of IMMray PanCan-d. The verification study analysis exhibits results in line with the previous commercial test model study (CTMS), which opens the way for the final blinded validation study.
The company is highly pleased with the verification study results and is now commencing the preparation for the validation process while finishing up some bioinformatics for all subgroups of samples. These results will be made public as fast as the study is completed in all its details. The company remains fully committed to the release of IMMray PanCan-d and are now only one step away from the Q4 start sales of IMMray PanCan-d.
The study was conducted to verify the IMMray PanCan-d commercial biomarker signature using samples and to further validate its accuracy in differentiating PDAC (pancreatic ductal adenocarcinoma) stages I via IV vs. controls that best mirror the clinical, commercial setting situation that is patients with non-specific but concerning symptoms. All the samples were freshly gathered through its Key Opinion Leaders (KOL) at pancreatic illnesses reference sites in the USA and Europe. The verification study precedes the last blinded validation test required for sales start.
Immunovia AB is a diagnostic firm producing and commercializing highly accurate blood tests for the early identification of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique disease biomarker signature.
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sergey Cherkasov, CIO, PhosAgro
By Pascal Becotte, MD-Global Supply Chain Practice for the...
By Stephen Caulfield, Executive Director, Global Field...
By Shamim Mohammad, SVP & CIO, CarMax
By Ronald Seymore, Managing Director, Enterprise Performance...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
By Jim Whitehurst, CEO, Red Hat
By Clark Golestani, EVP and CIO, Merck
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
By Amit Bahree, Executive, Global Technology and Innovation,...
By Greg Tacchetti, CIO, State Auto Insurance